The non-steroids antiinflammatory and antirheumatic medicine sales in Canada forecast reveals stable performance from 2024 through 2028. The sales remain consistent at 0.8 of total sales in 2024 and 2025, reducing slightly to 0.7 from 2026 onwards. Compared to 2023, where the value was also estimated at 0.8, this represents no significant change through to 2025 and a downward adjustment starts appearing in 2026 and holds steady thereafter. The compounded annual growth rate over this period highlights a stable yet slightly tapering trend in market share.
Future trends to watch for in this segment include:
- Potential advancements in alternative treatments that might affect antiinflammatory and antirheumatic medicine demands.
- Impact of demographic changes as the aging population increases the need for such medications.
- Policy shifts or healthcare reforms that could alter market dynamics.
